News und Analysen
UnitedHealth Sees a Healthier Future
Healthcare is front and center in Washington once more, and lawmakers have made little progress toward making anticipated changes on the insurance front. In the absence of more reform efforts, health
Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic
Johnson & Johnson (NYSE: JNJ) owes much of its recent success to the strength of its pharmaceutical division. Even though the company also has extensive exposure to other parts of the healthcare
5 Big Pharma Stocks With the Best Drug Pipelines
Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.Market research firm
5 Ways Gilead Sciences Could Spend Its Cash Hoard
Gilead Sciences (NASDAQ: GILD) has a growth problem.Long known for its enormous HIV franchise and market share, Gilead branched out into hepatitis C (HCV) in 2012. While that market provided plenty of
Forget GW Pharmaceuticals: These 2 Stocks Are Better Buys
Yes, GW Pharmaceuticals (NASDAQ: GWPH) is the biggest marijuana-focused biotech stock on the market. The company's promising cannabinoid Epidiolex could very well become a blockbuster success story in
3 Healthcare Stocks for Ambitious Investors
While we Fools generally prefer to invest in companies that have battle-tested business models, we do recognize that it can be a smart idea to swing for the fences every now and then.So which stocks
4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results
It's that time again, folks: Earnings season is kicking into full swing. And with that comes healthcare conglomerate Johnson & Johnson's (NYSE: JNJ) quarterly report, which often sets the tone for the
Should Mazor Robotics' Investors Fear the Incoming Competition?
Many industry experts believe that the robotic surgery market is on the cusp of a dramatic expansion. For example, a recent report from marketsandmarkets.com predicts that the market will grow from
3 Small Biotech Stocks Being Run by Proven Winners
Great leaders are important in any industry, but perhaps they're even more valuable in biotech, where any number of clinical-stage and regulatory obstacles can derail drug research and send share
Will the Drug Pricing Executive Order Help Big Pharma?
The cost of healthcare has climbed at a rate considerably above that of inflation, and high drug costs are a big factor. During his campaign, President Trump indicated that he would take steps to
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Pfizer (NYSE: PFE) stands at the top of the mountain when it comes to prescription drug sales. Last year, the big pharma company made $45.9 billion from prescription drugs, well ahead of runners-up
These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition
Pretty much everyone familiar with Gilead Sciences (NASDAQ: GILD) wants the company to make an acquisition. Many think the big biotech desperately needs one (or more) to reenergize the lethargic
Roundtable: 1 Stock I'm Never Selling
Stocks that are worth buying and holding for exceptionally long periods of time are far less common than most investors may think. Changes in underlying market conditions, after all, can knock even
What Managed Care Organizations Are, and How Investors Can Profit From Them
Most Americans get their healthcare through a managed care organization, but nearly no one truly knows the ins and outs of the health insurance program they have. Managed care organizations are plans
3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months
Although there is some truth in the saying that it takes money to make money, that doesn't mean investors can't start small and reap big rewards. With little more than $1,000 in your account, you can
Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?
Despite a widespread rally across the biotech landscape last month, the struggling clinical-stage cancer company Celldex Therapeutics (NASDAQ: CLDX) still managed to shed 14.8% of its value in
A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared
A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE: NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or
How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug
Here's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back
Investors in Alder Biopharmaceuticals (NASDAQ: ALDR) are having another wild day. Shares of the clinical-stage biopharma rose as much as 15.5% on Thursday after the company released the pricing
Johnson & Johnson Looks for Second-Quarter Strength to Keep Upward Momentum
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) has been immensely successful over the years, and it has also done well for shareholders recently. With a nearly 15% rise so far in 2017, Johnson
Henry Schein – Ausbruch oder Doppeltop?
Liebe Leser,
zu den Aktien mit der besten Kursperformance seit Ende der Finanzkrise 2009 gehört das Papier von Henry Schein. Von rund 33 US-Dollar ging es hinauf bis auf 180 US-Dollar im....
Amgen: Blockbuster-Medikamente-Umsatz macht Anleger stutzig!
Lieber Leser,
das am Umsatz gemessen weltgrößte Biotech-Unternehmen Amgen führt insgesamt sieben Blockbuster-Medikamente, die jeweils mehr als 1 Mrd. US-Dollar jährlich an Umsatz generieren. Das....
Gilead Sciences: Short-Investoren freuen sich
Lieber Leser,
Gilead Sciences ist in den vergangenen Handelssitzungen recht deutlich unter die Räder gekommen. Die Aktie verlor binnen zweier Wochen annähernd 7 %. Die Kurse gingen seit....
Gilead Sciences Inc.: Die Analyse!
Liebe Leser,
letzte Woche beschäftigten die Nachrichten zu Gilead Sciences die Gemüter der Anleger. Denn Clemens van Baaijen hat sich das Unternehmen und seine Aktie in einer 3-Stufen-Analyse....
Allergan: Warum bricht der Kurs ein?
Lieber Leser,
nachdem Allergan die Analysteneinschätzungen per Q1 2017 übertreffen konnte, verzeichnet die Aktie in den letzten beiden Wochen dennoch einen starken Kursverfall. Das....